Paris, 11 February 2013 - Following TAT, the International Congress on Targeted Anticancer Therapies, from 4 to 6 March in Paris, the Paris Region Economic Development Agency is organizing the first tour of leading clinical cancer research centers located in the Paris Region. Taking place on 7 March, this will be a unique opportunity for biotech companies to meet European researchers with a view to establishing new partnerships and speeding up the development of new therapies.

“Clinical research gives patients access to therapeutic innovation at an early stage. This is an area in which France has a substantial lead over its European neighbors,” states Frédérique de Bast, Chief Marketing Officer at Paris Region Economic Development Agency.

The program for this exceptional science tour includes an introduction to the Cancéropôle Cancer Research Cluster and AP-HP - Paris Public Hospital Authority - oncology research centers, visits to the Curie and Gustave Roussy institutes and the Sanofi European Oncology Research Center.

More than half of all advanced-level scientific oncology publications originate in the Paris Region, and the message from Dr.Jean-Pierre Armand, member of the TAT Congress scientific committee, to research biotechs is clear: “Base yourselves in Paris! You will find yourselves in an academic world that will support the development of your anticancer treatments and therapies.”

Visit of the Institut Curie clinical and translational research department

One of Paris Region’s world-renowned comprehensive cancer centers

Professor Sergio Roman-Roman, Head of Translational Research

Professor Christophe Letourneau, Head of Clinical Research

Sanofi research center, Vitry

Visit tof the Sanofi research center

This site is the Sanofi’s European R&D Center for Oncology

Dr.Céline Melcion, Head of the Research Center

Networking Lunch

Institut Gustave Roussy, Cancer Campus site, Villejuif

Visit to the Institut Gustave Roussy’s early clinical and translational research department led by Professor Jean-Charles Soria

One of Paris Region’s world-renowned comprehensive cancer centers

Professor Gilles Vassal, Head of Clinical Research

Dr. Eric Angevin, Clinical Investigator

Registration is essential as places are limited

To register, click here or contact: posttattour@paris-region.com

Open to all international biotech company employees attending TAT. Applications for the tour should be made at the same time as registration for the Oncology Biotech Event.

Press Contact

Aude Colonna: acolonna@paris-region.com - Tel: +33 (0)1 58 18 69 53

About Paris Region Economic Development Agency

Founded in 2001, the Paris Region Economic Development Agency (PREDA) helps attract new investment to the region to foster development and generate employment. PREDA has developed an array of services to assist businesses looking to set up and grow their business in Paris Region. These services cover all the main aspects of setting up: seeking premises and recruiting staff, advice on tax, legal matters and strategy for sustainable development, identifying commercial partners and R&D.

PREDA also has offices in Boston, San Francisco, Shanghai and Tel Aviv. Through the “Paris Region enterprises” program, PREDA supports Paris Region companies with plans to expand internationally.
For more information about PREDA, visit: www.paris-region.com,
Follow us on http://twitter.com/ParisRegion and Youtube: Paris Region Channel

About the TAT Congress

From 4-6 March 2013, Paris will be hosting the International Congress on Targeted Anticancer Therapies. This meeting for leading specialists in phase 1 clinical trials brings together researchers and laboratories from around the world to update them on the latest progress in oncology and associated projects in the Paris Region.

The TAT 2013 Congress will feature the Oncology Biotech Event, a special event focusing on business-to-academia partnering and networking for biotech companies.

This event, the first of its kind, will offer biotech companies a unique opportunity to interact closely with leading oncology phase 1 investigators and to showcase their innovations in oncology to the cancer research and development community.
TAT offers biotech firms developing an oncology drug the following benefits:

• Technology display: network within the higly specialized international oncology phase I research community

• Tour: visit leading clinical cancer research centers in the Paris region (AP-HP, Institut Curie, Institut Gustave Roussy, Sanofi), meet their heads of translational and early-stage clinical research with whom you could work with to develop your drug

For more information: http://www.tatcongress.org/progr-tat13.html #Biotech